MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics AG • MoonLake Immunotherapeutics Ltd • MNLK Immunotherapeutics, Unipessoal Lda, a private limited company incorporated ...

MLTX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

7 Nov 24

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

7 Nov 24

8-K

Regulation FD Disclosure

11 Sep 24

8-K

Regulation FD Disclosure

10 Jun 24

8-K

Submission of Matters to a Vote of Security Holders

7 May 24

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

7 May 24

10-K/A

2023 FY

Annual report (amended)

7 May 24

ARS

2023 FY

Annual report to shareholders

24 Apr 24

Latest ownership filings

View all

BIOTECHNOLOGY VALUE FUND L P

Financial summary

Financial statements Chart MLTX financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	375.66 mm	375.66 mm	375.66 mm	375.66 mm	375.66 mm	375.66 mm
Cash burn (monthly)	27.59 mm	10.51 mm	14.37 mm	7.58 mm	12.04 mm	6.05 mm
Cash used (since last report)	77.24 mm	29.42 mm	40.23 mm	21.21 mm	33.70 mm	16.95 mm
Cash remaining	298.41 mm	346.24 mm	335.43 mm	354.44 mm	341.96 mm	358.71 mm
Runway (months of cash)	10.8	32.9	23.3	46.8	28.4	59.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

MLTX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	112	1	+11100.0%
Opened positions	111	0	NEW
Closed positions	0	127	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	2.54 tn	1.13 bn	+225049.2%
Total shares	82.40 mm	21.75 mm	+278.8%
Total puts	75.20 k	0.00	NEW
Total calls	100.60 k	0.00	NEW
Total put/call ratio	0.7	–	–

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	21.75 mm	$1.13 bn	0.0%
BVF	21.75 mm	$956.40 bn	NEW
Cormorant Asset Management	8.49 mm	$373.49 bn	NEW
FMR	3.64 mm	$160.23 bn	NEW
Avoro Capital Advisors	2.77 mm	$121.80 bn	NEW
T. Rowe Price	2.56 mm	$112.63 mm	NEW
Citadel Advisors	2.27 mm	$99.62 bn	NEW
Adage Capital Partners GP, L.L.C.	1.83 mm	$80.25 bn	NEW
Holocene Advisors	1.63 mm	$71.51 bn	NEW
GS The Goldman Sachs Group, Inc.	1.25 mm	$55.04 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BVF	21.75 mm	+21.75 mm	NEW
Cormorant Asset Management	8.49 mm	+8.49 mm	NEW
FMR	3.64 mm	+3.64 mm	NEW
Avoro Capital Advisors	2.77 mm	+2.77 mm	NEW
T. Rowe Price	2.56 mm	+2.56 mm	NEW
Citadel Advisors	2.27 mm	+2.27 mm	NEW
Adage Capital Partners GP, L.L.C.	1.83 mm	+1.83 mm	NEW
Holocene Advisors	1.63 mm	+1.63 mm	NEW
GS The Goldman Sachs Group, Inc.	1.25 mm	+1.25 mm	NEW
FHI Federated Hermes	1.13 mm	+1.13 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MLTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Oct 24	Partners L P/il BVF	Class A Ordinary Shares, $0.0001 par value	Sell	Dispose S	No	No	50.0016	132,549	6.63 mm	1,287,768
4 Oct 24	Partners L P/il BVF	Class A Ordinary Shares, $0.0001 par value	Sell	Dispose S	No	No	50.0016	836,862	41.84 mm	8,168,838
4 Oct 24	Partners L P/il BVF	Class A Ordinary Shares, $0.0001 par value	Sell	Dispose S	No	No	50.0016	1,030,589	51.53 mm	10,235,089
4 Oct 24	Simon Sturge	Class A ordinary shares, par value $0.0001 per share	Sell	Dispose S	No	No	53.72	171,000	9.19 mm	171,980
6 Jun 24	Spike Loy	Option to Buy Class A ordinary shares, par value $0.0001 per share	Grant	Acquire A	No	No	42.44	7,688	326.28 k	7,688
6 Jun 24	Moukheibir Catherine	Option to Buy Class A ordinary shares, par value $0.0001 per share	Grant	Acquire A	No	No	42.44	7,688	326.28 k	7,688
6 Jun 24	Simon Sturge	Option to Buy Class A ordinary shares, par value $0.0001 per share	Grant	Acquire A	No	No	42.44	7,688	326.28 k	7,688

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

14 Nov 24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

8 Nov 24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.

Wedbush Assumes MoonLake at Outperform, Lowers Price Target of $73

5 Nov 24

Wedbush analyst Yun Zhong assumes MoonLake (NASDAQ:MLTX) with a Outperform rating and lowers Price Target of $73.

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

15 Oct 24

Press releases

From Benzinga Pro

Clear Street Launches Healthcare & Biotechnology Equity Research

17 Dec 24

Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a